Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

The European Medicines Agency's committee on Friday recommended extending ‍the use of Eli Lilly's blockbuster drug Mounjaro ...